Tricuspid valve failure with low output state is a growing problem in the management of structural heart disease and stage D heart failure. Severe tricuspid valve disease either due to congenital or acquired etiology constitutes high risk for palliative or definitive surgical correction. Limited progress is noted so far on the evolution of durable surgical techniques on tricuspid valve disease and spiraling down refractory right heart failure continues to be the Achilles heel in the management. Over the last decade, transcatheter therapies for the management of aortic and pulmonary valves have expanded the therapeutic options for patients deemed at high risk for conventional surgery. The interventional therapies to manage tricuspid valve failure have mostly been a surrogate use of established therapies for other valves. The numerous interventional strategies used on failing tricuspid valve include percutaneous tricuspid valvuloplasty, percutaneous valve in valve, valve-in-ring implantation, and orthotopic/ heterotopic valve implantation using commercially available "off-label" device or dedicated custom-made devices. This review focuses on the different percutaneous approaches and devices that have evolved for the management of tricuspid valve failure with varying anatomical substrates such as native tricuspid valves, annuloplasty rings or bioprosthesis.